Valuation: Mangalam Drugs & Organics Limited

Market Cap 53Cr 54.93L 47.58L 44.99L 40.73L 76.45L 77.02L 5.37Cr 2.07Cr 27Cr 2.06Cr 2.02Cr 85Cr P/E 2025
17.5x
P/E 2026 -0.99x
Enterprise Value 164.74Cr 1.72Cr 1.49Cr 1.41Cr 1.27Cr 2.39Cr 2.41Cr 17Cr 6.46Cr 84Cr 6.45Cr 6.31Cr 266.4Cr EV / Sales 2025
0.66x
EV / Sales 2026 0.67x
Free-Float
62.31%
Yield 2025 *
-
Yield 2026 -
17/08 Mangalam Drugs and Organics Limited Discloses Default on Bank Loan Accounts with Bank of Baroda and Bank of Maharashtra CI
13/08 Mangalam Drugs & Organics Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
18/06 Mangalam Drugs and Organics Ltd. Defaults on Loan Obligations to Bank of Baroda and Bank of Maharashtra CI
14/05 Mangalam Drugs & Organics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
17/04 Mangalam Drugs & Organics Limited Announces Resignation of Anuradha Pandey as Company Secretary & Compliance Officer, Effective March 29, 2026 CI
16/04 Mangalam Drugs and Organics Limited Defaults on Loan Obligations Exceeding 30 Days with INR 95.197 Million to Bank of Maharashtra and INR 60.608 Million to Bank of Baroda CI
26/03 Mangalam Drugs and Organics Limited Appoints Shweta Patel as Company Secretary & Compliance Officer, Effective April 1, 2026 CI
17/03 Mangalam Drugs and Organics Limited Reports Loan Defaults Exceeding 30 Days on Bank Borrowings CI
17/03 Mangalam Drugs and Organics Limited Defaults on Loan Obligations to Bank of Maharashtra and Bank of Baroda CI
17/03 Mangalam Drugs and Organics Limited Defaults on Bank Loan Obligations Exceeding 30 Days with INR 70.705 Million to Bank of Maharashtra and INR 44.677 Million to Bank of Baroda CI
17/03 Mangalam Drugs and Organics defaults on loan obligations to Bank of Baroda, Bank of Maharashtra RE
06/02 Mangalam Drugs and Organics names Jeevan M. Dalvi as CFO RE
06/02 Mangalam Drugs and Organics Limited Approves the Appointment of Jeevan Mukund Dalvi as Chief Financial Officer, Effective February 6, 2026 CI
1 day-4.41%
1 week+1.10%
Current month+1.01%
1 month+15.16%
3 months+7.98%
6 months+5.11%
Current year+16.54%
1 week 31.71
Extreme 31.71
38.25
1 month 26.14
Extreme 26.14
38.25
Current year 25.7
Extreme 25.7
54.4
1 year 22.8
Extreme 22.8
77.6
3 years 22.8
Extreme 22.8
144.99
5 years 22.8
Extreme 22.8
173
10 years 20.65
Extreme 20.65
225.7
Manager TitleAgeSince
Chief Executive Officer 72 30/09/2011
Director of Finance/CFO - 06/02/2026
Compliance Officer 27 01/04/2026
Director TitleAgeSince
Chairman 72 02/02/2010
Director/Board Member 75 05/02/2015
Director/Board Member 38 28/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.88%+1.10% - - 54.93L
+0.66%-0.83%+14.83%+61.15% 4.59TCr
-4.55%-6.60%+28.67%+95.78% 3.87TCr
-0.18%-2.67%+6.07%+70.55% 1.14TCr
+0.32%-0.60%-13.09%+9.22% 1.14TCr
-0.95%0.00%+19.82%+146.45% 908.8Cr
+0.80%+0.64%+24.85%+37.61% 729.75Cr
+0.66%-1.93%+14.98%+180.44% 697.73Cr
-1.00%-0.98%+33.68%-20.38% 712.96Cr
-2.15%-4.76%-44.26%+4.59% 488.51Cr
Average -1.06%-2.24%+9.51%+65.04% 1.59TCr
Weighted average by Cap. -1.08%-2.68%+15.41%+71.20%

Financials

2025 2026
Net sales 317.58Cr 3.31Cr 2.87Cr 2.71Cr 2.45Cr 4.61Cr 4.64Cr 32Cr 12Cr 161.03Cr 12Cr 12Cr 513.54Cr 232.13Cr 2.42Cr 2.1Cr 1.98Cr 1.79Cr 3.37Cr 3.39Cr 24Cr 9.1Cr 117.7Cr 9.09Cr 8.89Cr 375.38Cr
Net income 6.72Cr 7L 6L 6L 5L 10L 10L 68.48L 26.35L 3.41Cr 26.32L 25.73L 11Cr -44Cr -46.29L -40.09L -37.91L -34.32L -64.42L -64.9L -4.52Cr -1.74Cr -23Cr -1.74Cr -1.7Cr -72Cr
Net Debt 94Cr 97.62L 84.56L 79.96L 72.39L 1.36Cr 1.37Cr 9.54Cr 3.67Cr 47Cr 3.67Cr 3.59Cr 151.42Cr 112.05Cr 1.17Cr 1.01Cr 95.68L 86.62L 1.63Cr 1.64Cr 11Cr 4.39Cr 57Cr 4.39Cr 4.29Cr 181.2Cr
Logo Mangalam Drugs & Organics Limited
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Employees
319
Date Price Change Volume
16/26/16 32.24 -3.88% 41,578
15/26/15 ₹33.54 -8.01% 1,09,928
11/26/11 ₹36.46 +4.53% 3,85,169
10/26/10 ₹34.88 +10.00% 2,84,790
09/26/09 ₹31.71 +8.11% 64,156
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!